Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited (SEHK: 1177|Hang Seng Index component) (simplified Chinese: 中国生物制药有限公司; traditional Chinese: 中國生物製藥有限公司; pinyin: zhōng guó shēng wù zhì yào yǒu xiàn gōng sī), shortly Sino Biopharm, is a civilian-run enterprise principally engaged in the medicine products business in Mainland China.
Type | listed | ||||||
---|---|---|---|---|---|---|---|
| |||||||
Industry | Pharmaceutical | ||||||
Founded | 2000 | ||||||
Headquarters | , | ||||||
Area served | People's Republic of China | ||||||
Key people | Executive chairwoman: Ms. Theresa Tse CEO: Mr. Yi Li[1][2] | ||||||
Parent | Charoen Pokphand Group | ||||||
Chinese name | |||||||
Simplified Chinese | 中国生物制药有限公司 | ||||||
Traditional Chinese | 中國生物製藥有限公司 | ||||||
| |||||||
Chinese short name | |||||||
Simplified Chinese | 中生制药 | ||||||
Traditional Chinese | 中生製藥 | ||||||
| |||||||
second alternative short name | |||||||
Simplified Chinese | 中国生物制药 | ||||||
Traditional Chinese | 中國生物製藥 | ||||||
| |||||||
Website | Sino Biopharmaceutical Limited |
Being a member of Charoen Pokphand Group and headquartered in Hong Kong and Beijing, Sino Biopharm is engaged in researching, developing, producing, and selling biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis through its subsidiaries.[3]
Sino Biopharm is also involved in other minor businesses through its subsidiaries, such as properties, health food, optical glass, optical and auditory products.[4]
References
-
"Sino Biopharmaceutical Limited: Profile". Retrieved 2021-05-26.
Ms. Y. Y. Tse - Exec. Chairman... Mr. Yi Li - CEO & Exec. Director
- "Sino Biopharmaceutical Limited 1177.HK: People". Reuters. Retrieved 2021-05-26.
Y. Y. Tse - 26 - Executive Chairwoman of the Board, Yi Li - 59 - Chief Executive Officer, Executive Director
- "Sino Biopharmaceutical | Company Overview & News". Forbes. Archived from the original on 2023-05-23.
- About the company